Literature DB >> 15742433

Prediction of mortality in rheumatoid arthritis based on disease activity markers.

Christina Book1, Tore Saxne, Lennart T H Jacobsson.   

Abstract

OBJECTIVE: The risks and predictors for mortality in patients with rheumatoid arthritis (RA) were examined in a cohort of 152 consecutive outpatients (119 women, 33 men) seen in a 2 month period.
METHODS: We evaluated 4 measures of disease activity: erythrocyte sedimentation rate (ESR), physician and patient global assessment of disease activity, and the Ritchie Articular Index (RAI) as mortality predictors, adjusting for disease severity, treatment, and cardiovascular disease (CVD) comorbidity.
RESULTS: During followup from 1978 through 1998, 111 patients (86 women, 25 men) died, and only one was lost to followup. The standardized mortality ratio for women was 161 (95% confidence interval 129-199), for men 152 (95% CI 99-223), and for both sexes combined 156 (95% CI 128-188). In a proportional hazards model adjusted for age and sex, at the beginning of the period and for the whole group, significant predictors of mortality were Steinbrocker functional class, Larsen index, CVD comorbidity, use of corticosteroids ever, ESR, and the physician and patient global assessment of disease activity; but the rheumatoid factor (RF), RAI, and use of disease modifying antirheumatic drugs were not significant predictors. When evaluating the 4 assessments of disease activity adjusting for confounders, only physician global assessment hazard ratio (HR) = 1.32 per 1 SD (95% CI 1.00-1.74) and ESR HR = 1.47 per 1 SD (95% CI 1.11-1.93) were significant predictors.
CONCLUSION: This longterm followup study of a single clinical patient cohort showed a significant increase in mortality among patients with RA compared to the general population in Malmö. In addition to disease damage and CVD comorbidity, measures of disease activity independently predicted mortality, which supports the hypothesis that improving these variables may also improve longterm outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15742433

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  18 in total

1.  Red cell distribution width: a measure of cardiovascular risk in rheumatoid arthritis patients?

Authors:  Sobia Hassan; Maria Antonelli; Stanley Ballou
Journal:  Clin Rheumatol       Date:  2015-04-24       Impact factor: 2.980

2.  Designing a decision support system for existing clinical organizational structures: considerations from a rheumatology clinic.

Authors:  Orjan Dahlström; Ingrid Thyberg; Ursula Hass; Thomas Skogh; Toomas Timpka
Journal:  J Med Syst       Date:  2006-10       Impact factor: 4.460

Review 3.  Cardiovascular safety of biologic therapies for the treatment of RA.

Authors:  Jeffrey D Greenberg; Victoria Furer; Michael E Farkouh
Journal:  Nat Rev Rheumatol       Date:  2011-11-15       Impact factor: 20.543

Review 4.  Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment.

Authors:  Mariana J Kaplan
Journal:  Rheum Dis Clin North Am       Date:  2010-05       Impact factor: 2.670

5.  Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.

Authors:  Calin Popa; Frank H J van den Hoogen; Timothy R D J Radstake; Mihai G Netea; Agnes E Eijsbouts; Martin den Heijer; Jos W M van der Meer; Piet L C M van Riel; Anton F H Stalenhoef; Pilar Barrera
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

Review 6.  Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Ruben-Dario Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 7.  Prognostic factors in rheumatoid arthritis in the era of biologic agents.

Authors:  Alla Skapenko; Iryna Prots; Hendrik Schulze-Koops
Journal:  Nat Rev Rheumatol       Date:  2009-07-28       Impact factor: 20.543

8.  Interpreting studies of cardiovascular mortality in rheumatoid arthritis: the importance of timing.

Authors:  Michael M Ward
Journal:  Arthritis Rheum       Date:  2008-12-15

9.  Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis.

Authors:  Jonathan Graf; Rebecca Scherzer; Carl Grunfeld; John Imboden
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

10.  Association of circulating levels of MMP-8 with mortality from respiratory disease in patients with rheumatoid arthritis.

Authors:  Derek L Mattey; Nicola B Nixon; Peter T Dawes
Journal:  Arthritis Res Ther       Date:  2012-10-02       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.